Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of a placebo and corifollitropin alfa. Corifollitropin alfa is a long-acting recombinant fusion protein analog of follicle-stimulating hormone (FSH), used primarily for controlled ovarian stimulation in women undergoing assisted reproductive technology (ART) procedures such as in vitro fertilization. It acts as an FSH receptor agonist, stimulating the development of multiple ovarian follicles over a sustained period with a single injection, thereby reducing the need for daily FSH injections. In adolescent males with hypogonadotropic hypogonadism, it is used in combination with human chorionic gonadotropin (hCG) to stimulate testicular growth and spermatogenesis. The placebo component has no pharmacological activity and serves as an inactive comparator or control in clinical trials.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on placebo + corifollitropin alfa.